ALDH18A1 and metabolic dysfunction-associated steatotic liver disease: Notwithstanding these limitations, we validate that the GPR could be used as a non-invasive marker to predict liver fibrosis and cirrhosis for CHB-NAFLD individuals, especially when compared with APRI and FIB-4.